Clinical trials: mRNA Vaccination, open to volunteers
Chlamydia Trachomatis Immunization
Phase 1 Study of Chlamydia Trachomatis mRNA Vaccine in Adults.
The purpose of this study is to evaluate the safety of two doses (Dose 1 and Dose 2) of Chlamydia mRNA Vaccine candidate in adult participants aged 18 to 29 years (Chlamydia trachomatis seronegative) or 18 to 44 years (Chlamydia…
- Trial name
- NCT06891417
- Testing
- Chlamydia mRNA Vaccine
- Where
- 7 sites in Australia
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Sanofi
Genital Herpes
A Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of an mRNA Vaccine Against Herpes Simplex Virus Type 2 (HSV-2) Post-Vaccination
A Preliminary Evaluation of the Safety and Immunogenicity Post-Vaccination with Different Doses of an mRNA Vaccine against Herpes Simplex Virus Type 2 (HSV-2) in Populations with Different Serostatus
- Trial name
- NCT07330440
- Testing
- Low-Dose Cohort, Mid-Dose Cohort, High-Dose Cohort
- Where
- China
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Changchun BCHT Biotechnology Co.
Mpox (Monkeypox), Smallpox
A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa
This is a randomized, double-blind, placebo-controlled study which aims to assess the safety, reactogenicity, and immunogenicity after one and two doses of BNT166a or placebo in healthy participants.
- Conditions
- Mpox (Monkeypox), Smallpox, Orthopoxvirus Infection
- Trial name
- NCT07379580
- Testing
- BNT166a
- Where
- 6 sites in Democratic Republic of the Congo, South Africa
- Volunteers
- 310 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Healthy Adults
A Study to Learn About mRNA Vaccines Against Influenza in Adults
The purpose of this study is to learn about safety in participants taking the study vaccine (mRNA-based vaccine) and the ability of the study vaccine to trigger the body's immune response, targeting the flu virus (influenza…
- Trial name
- NCT07431853
- Testing
- Vaccine Candidate #1, Vaccine Candidate #2, Vaccine Candidate #3
- Where
- 15 sites in United States
- Volunteers
- 770 people, healthy volunteers welcome
- Sponsor
- Pfizer